Literature DB >> 2461519

HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides.

D F Nixon1, A R Townsend, J G Elvin, C R Rizza, J Gallwey, A J McMichael.   

Abstract

Current candidate vaccines fail to protect primates against challenge with human immunodeficiency virus (HIV) in the presence of antibody responses; this underlines the importance of studying cell-mediated immunity to HIV and identifying specific epitopes that stimulate cytotoxic T lymphocytes (CTL). Using a recombinant vaccinia virus to express the gag protein of HIV-1 we found HLA class-I-restricted gag-specific CTL in thirteen out of fifteen healthy HIV seropositive patients. We then used short synthetic peptides in the lysis assay to screen for gag CTL epitopes. In one patient we have identified a peptide in p24 that is recognized by CTL in association with HLA-B27. This peptide, and further peptide sequences defined by these methods, could be incorporated in vaccines designed to induce cell-mediated immunity against HIV.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461519     DOI: 10.1038/336484a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  155 in total

1.  A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.

Authors:  P A Goepfert; A Bansal; B H Edwards; G D Ritter; I Tellez; S A McPherson; S Sabbaj; M J Mulligan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  How cytotoxic T cells manage to discriminate nonself from self at the nonapeptide level.

Authors:  S Ohno
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

3.  Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes.

Authors:  L C Dai; K West; R Littaua; K Takahashi; F A Ennis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

Review 4.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 5.  Role of class I molecules of the major histocompatibility complex in cytotoxic T-cell function in health and disease.

Authors:  A J McMichael
Journal:  Springer Semin Immunopathol       Date:  1992

6.  Transcriptional profiling of experimental CD8(+) lymphocyte depletion in rhesus macaques infected with simian immunodeficiency virus SIVmac239.

Authors:  Steven E Bosinger; Simon P Jochems; Kathryn A Folkner; Timothy L Hayes; Nichole R Klatt; Guido Silvestri
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

7.  Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein.

Authors:  R S van Binnendijk; J P Versteeg-van Oosten; M C Poelen; H F Brugghe; P Hoogerhout; A D Osterhaus; F G Uytdehaag
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens.

Authors:  C Jassoy; T Harrer; T Rosenthal; B A Navia; J Worth; R P Johnson; B D Walker
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

9.  Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates.

Authors:  M J Irwin; L S Laube; V Lee; M Austin; S Chada; C G Anderson; K Townsend; D J Jolly; J F Warner
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection.

Authors:  M C Aldhous; K C Watret; J Y Mok; A G Bird; K S Froebel
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.